For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
After finishing at $4.58 in the prior trading day, ATAI Life Sciences N.V (NASDAQ: ATAI) closed at $4.59, up 0.22%. In other words, the price has increased by $0.22 from its previous closing price. On the day, 3.27 million shares were traded. ATAI stock price reached its highest trading level at $4.76 during the session, while it also had its lowest trading level at $4.42.
Ratios:
Our goal is to gain a better understanding of ATAI by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.02 and its Current Ratio is at 4.02. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Oppenheimer on July 29, 2025, initiated with a Outperform rating and assigned the stock a target price of $14.
On November 18, 2024, H.C. Wainwright reiterated its Buy rating and also upped its target price recommendation from $15 to $10. Maxim Group Upgraded its Hold to Buy on April 03, 2024, while the target price for the stock was maintained at $6.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 14 ’25 when Apeiron Investment Group Ltd. bought 8,675,799 shares for $2.19 per share. The transaction valued at 19,000,000 led to the insider holds 51,045,214 shares of the business.
SAHIL KIRPEKAR bought 83,332 shares of ATAI for $233,830 on Jul 02 ’25. On Jul 01 ’25, another insider, SAHIL KIRPEKAR, who serves as the Officer of the company, bought 106,093 shares for $2.77 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ATAI now has a Market Capitalization of 983811456 and an Enterprise Value of 897629568. For the stock, the TTM Price-to-Sale (P/S) ratio is 2981.25 while its Price-to-Book (P/B) ratio in mrq is 6.78. Its current Enterprise Value per Revenue stands at 388.753 whereas that against EBITDA is -9.464.
Stock Price History:
The Beta on a monthly basis for ATAI is 1.56, which has changed by 2.762295 over the last 52 weeks, in comparison to a change of 0.16222072 over the same period for the S&P500. Over the past 52 weeks, ATAI has reached a high of $5.34, while it has fallen to a 52-week low of $1.03. The 50-Day Moving Average of the stock is 31.05%, while the 200-Day Moving Average is calculated to be 116.42%.
Shares Statistics:
The stock has traded on average 5.92M shares per day over the past 3-months and 6087220 shares per day over the last 10 days, according to various share statistics. A total of 212.24M shares are outstanding, with a floating share count of 136.72M. Insiders hold about 36.21% of the company’s shares, while institutions hold 12.56% stake in the company. Shares short for ATAI as of 1755216000 were 15325335 with a Short Ratio of 2.59, compared to 1752537600 on 16175083. Therefore, it implies a Short% of Shares Outstanding of 15325335 and a Short% of Float of 9.15.
Earnings Estimates
The current market rating for ATAI Life Sciences N.V (ATAI) reflects the collective analysis of 6.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.12, with high estimates of -$0.07 and low estimates of -$0.19.
Analysts are recommending an EPS of between -$0.43 and -$0.58 for the fiscal current year, implying an average EPS of -$0.5. EPS for the following year is -$0.47, with 5.0 analysts recommending between -$0.28 and -$0.9.
Revenue Estimates
A total of 9 analysts have provided revenue estimates for ATAI’s current fiscal year. The highest revenue estimate was $3.8M, while the lowest revenue estimate was $2.27M, resulting in an average revenue estimate of $2.46M. In the same quarter a year ago, actual revenue was $308k
